Evidence map›Paper›PMID 30755732›Full record

ArticleOncogene2019

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.

Francesco Alessandrini, Laura Menotti, Elisa Avitabile, Irene Appolloni, Davide Ceresa, Daniela Marubbi, Gabriella Campadelli-Fiume, Paolo Malatesta

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. [Theranostics · 2024
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Francesco AlessandriniDepartment of Experimental Medicine, University of Genoa, Genoa, Italy.
Laura MenottiDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Elisa AvitabileDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Irene AppolloniDepartment of Experimental Medicine, University of Genoa, Genoa, Italy.
Davide CeresaDepartment of Experimental Medicine, University of Genoa, Genoa, Italy.
Daniela MarubbiDepartment of Experimental Medicine, University of Genoa, Genoa, Italy.
Gabriella Campadelli-FiumeDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Paolo MalatestaDepartment of Experimental Medicine, University of Genoa, Genoa, Italy. paolo.malatesta@unige.it.
University of Genoa · ITUniversity of Bologna · ITOspedale Policlinico San Martino · IT

Funding

PREVALENCE AND SPECTRUM OF B12 DEFICIENCY IN THE AGEDR01AG009834 · NIA · UNIVERSITY OF COLORADO DENVER · PI STABLER, SALLY P · 1991 to 2007
$1.7M
6 · The paper itself

Abstract

Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.

Indexed as

AnimalsBrain NeoplasmsCell Line, TumorDisease Models, AnimalErb-b2 Receptor Tyrosine KinasesFemaleGlioblastomaHumansImmunotherapyInterleukin-12 Subunit p35Kaplan-Meier EstimateMaleMiceMice, Inbred BALB CMutationNeoplasm Recurrence, LocalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIl12a protein, mouseInterleukin-12 Subunit p35Proto-Oncogene Proteins c-sis

Identifiers

PMID30755732
OpenAlexW2912924134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.